Avita Medical touts ReCell skin graft study data

Avita Medical (ASX:AVH) today released data from a trial of its ReCell device used to treat skin graft patients, touting hastened healing and improved final outcomes.

The ReCell device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, reconstructive and cosmetic procedures, the company said.

Results from the 106-patient randomized controlled trial were published in the British Journal of Surgery, Cambridge, U.K.-based Avita said.

In the study, investigators explored whether donor sites for skin grafts healed faster or better if the company’s ReCell device alongside hydrocolloid dressing, the main standard of care. Researchers examined 106 patients over 18 months, and reported that median time to re-epithelialization was 9 days in the ReCell group, 4 days shorter than the 13 days reported in the control group.

“The autologous skin cell suspension is produced quickly and is available immediately for wound application. This study suggests that its use [on] skin graft donor [sites] should promote healing and improve long-term aesthetic results,” trial investigators wrote.

In evaluations of the donor sites, both patients and independent observers reported that the sites treated with autologous skin cell suspension “displayed better physical attributes” and patients were reportedly more satisfied with the healing quality.

“We are excited about these results, as together, the data show that ReCell can be deployed both to reduce patient trauma, and to help patients heal faster. Our pivotal trial in the US, announced last month, showed how ReCell allowed doctors to successfully treat burns using about 30% less donor skin. Now, in China, surgeons have shown that the donor site itself can heal some 30% faster when treated with Regenerative Epithelial Suspension made using the ReCell device. Demonstration of clinical benefit for treatment of burn injuries and treatment of donor sites further substantiates the key, versatile role for ReCell in burn care,” CEO Mike Perry said in a press release.

In May, Avita Medical saw shares rise over 5% after announcing that the pivotal clinical trial of its regenerative ReCell device for treating severe burns met both co-primary endpoints.

The post Avita Medical touts ReCell skin graft study data appeared first on MassDevice.

from MassDevice http://ift.tt/2rSBCSY